Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

K-111

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
This article is part of Ahmed M. Khalid's PhD thesis, which is available in Munin: http://hdl.handle.net/10037/1802 
  • table 1
  • table 2
  • table 3
  • figure 1
2007
2007
The relationship between adipocytes and infiltrated macrophages in fat tissue is important for the pathogenesis of insulin… Expand
Review
2007
Review
2007
  • B. Drew, A. Calkin
  • Current opinion in investigational drugs
  • 2007
  • Corpus ID: 45593092
Kozva Co Ltd, under license from Roche Holding AG, is developing K-111, an orally available peroxisome proliferator-activated… Expand
Review
2006
Review
2006
Introduction: Prevalence of the metabolic syndrome has increased dramatically in recent years. Optimal patient care demands a… Expand
  • table 1
  • table 2
  • figure 1
2004
2004
K-111 has been characterized as a potent peroxisome proliferator-activated receptor (PPAR)alpha activator. Antidiabetic potency… Expand
2003
2003
K-111, formerly BM 17.0744, (2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid) is a new insulin-sensitizer with peroxisome… Expand
2002
2002
This study was undertaken to investigate the hypocholesterolemic activity ofBifidobacteria (B. breve K-110,B. breve K-111, andB… Expand
2001
2001
Panax ginseng is widely used as a Chinese medicine, but it takes a long time to reach harvest and to establish its qualified… Expand
2000
2000
The antitumor activity ofBifidobacterium breve K-110, and K-111, andB. infantis K-525 was investigated. TheseBifidobacterial… Expand
1999
1999
The protective effect of Bifidobacterium breve K-110, K-111 and B. infantis K-525 on carbon tetrachloride induced hepatotoxicity… Expand